BidaskClub Upgrades Eagle Pharmaceuticals (NASDAQ:EGRX) to Buy

BidaskClub upgraded shares of Eagle Pharmaceuticals (NASDAQ:EGRX) from a hold rating to a buy rating in a research note published on Saturday, BidAskClub reports.

Other equities analysts have also issued reports about the stock. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a buy rating to a hold rating in a research report on Wednesday, July 10th. ValuEngine upgraded shares of Eagle Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, April 23rd. Cantor Fitzgerald reiterated a hold rating and issued a $58.00 price target on shares of Eagle Pharmaceuticals in a report on Tuesday, May 7th. Finally, Mizuho reiterated a hold rating and issued a $50.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, April 24th. Five research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Eagle Pharmaceuticals has an average rating of Hold and a consensus price target of $58.20.

Shares of Eagle Pharmaceuticals stock opened at $57.71 on Friday. The stock has a market cap of $793.84 million, a price-to-earnings ratio of 27.61 and a beta of 1.44. The company has a quick ratio of 3.36, a current ratio of 3.59 and a debt-to-equity ratio of 0.21. The firm has a 50 day moving average of $55.30. Eagle Pharmaceuticals has a 52 week low of $36.03 and a 52 week high of $82.33.

Eagle Pharmaceuticals (NASDAQ:EGRX) last announced its quarterly earnings data on Thursday, August 8th. The specialty pharmaceutical company reported $0.48 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.31 by $0.17. The firm had revenue of $56.70 million during the quarter, compared to analyst estimates of $53.61 million. Eagle Pharmaceuticals had a net margin of 19.79% and a return on equity of 24.10%. Eagle Pharmaceuticals’s revenue was down 4.4% on a year-over-year basis. During the same period last year, the firm posted $0.99 EPS. As a group, analysts anticipate that Eagle Pharmaceuticals will post 1.75 EPS for the current year.

A number of large investors have recently modified their holdings of EGRX. PNC Financial Services Group Inc. grew its stake in shares of Eagle Pharmaceuticals by 156.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 642 shares of the specialty pharmaceutical company’s stock worth $32,000 after purchasing an additional 392 shares during the period. Financial Gravity Wealth Inc. acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $33,000. First Quadrant L P CA acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $34,000. NumerixS Investment Technologies Inc acquired a new stake in shares of Eagle Pharmaceuticals during the 2nd quarter worth approximately $39,000. Finally, Bank of Montreal Can grew its stake in shares of Eagle Pharmaceuticals by 395.0% during the 2nd quarter. Bank of Montreal Can now owns 1,277 shares of the specialty pharmaceutical company’s stock worth $71,000 after purchasing an additional 1,019 shares during the period. Institutional investors own 96.61% of the company’s stock.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.

Featured Article: What is a blue-chip stock?

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.